Compile Data Set for Download or QSAR
Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 8218
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237099(US9388199, 8)
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237106(US9388199, 15)
Affinity DataIC50: 21nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237113(US9388199, 22)
Affinity DataIC50: 57nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237112(US9388199, 21)
Affinity DataIC50: 58nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237092(US9388199, 1)
Affinity DataIC50: 61nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237135(US9388199, 28)
Affinity DataIC50: 65nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237098(US9388199, 7)
Affinity DataIC50: 68nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237096(US9388199, 5)
Affinity DataIC50: 88nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237094(US9388199, 3)
Affinity DataIC50: 103nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237126(US9388199, 36)
Affinity DataIC50: 113nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237105(US9388199, 14)
Affinity DataIC50: 127nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237107(US9388199, 16)
Affinity DataIC50: 152nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237100(US9388199, 9)
Affinity DataIC50: 153nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237095(US9388199, 4)
Affinity DataIC50: 161nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237097(US9388199, 6)
Affinity DataIC50: 168nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237124(US9388199, 34)
Affinity DataIC50: 192nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237119(US9388199, 29)
Affinity DataIC50: 227nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237123(US9388199, 33)
Affinity DataIC50: 271nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237133(US9388199, 43)
Affinity DataIC50: 323nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237120(US9388199, 30)
Affinity DataIC50: 324nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237111(US9388199, 20)
Affinity DataIC50: 328nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237108(US9388199, 17)
Affinity DataIC50: 333nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237134(US9388199, 44)
Affinity DataIC50: 384nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237114(US9388199, 23)
Affinity DataIC50: 427nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237127(US9388199, 37)
Affinity DataIC50: 443nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237104(US9388199, 13)
Affinity DataIC50: 504nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237125(US9388199, 35)
Affinity DataIC50: 593nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237093(US9388199, 2)
Affinity DataIC50: 605nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237122(US9388199, 32)
Affinity DataIC50: 874nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237116(US9388199, 25)
Affinity DataIC50: 912nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237110(US9388199, 19)
Affinity DataIC50: 929nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237128(US9388199, 38)
Affinity DataIC50: 1.05E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237121(US9388199, 31)
Affinity DataIC50: 1.14E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237131(US9388199, 41)
Affinity DataIC50: 1.35E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237117(US9388199, 26)
Affinity DataIC50: 1.39E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237115(US9388199, 24)
Affinity DataIC50: 1.75E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237118(US9388199, 27)
Affinity DataIC50: 1.97E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237109(US9388199, 18)
Affinity DataIC50: 2.89E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237129(US9388199, 39)
Affinity DataIC50: 5.32E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237132(US9388199, 42)
Affinity DataIC50: 5.36E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237101(US9388199, 10)
Affinity DataIC50: 5.67E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237103(US9388199, 12)
Affinity DataIC50: 7.22E+3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237130(US9388199, 40)
Affinity DataIC50: 1.08E+4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM237102(US9388199, 11)
Affinity DataIC50: 1.46E+4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent